Oncology

Aptamer therapeutics in Oncology can be configured in various ways:

  • Antagonist of protein-protein or receptor-ligand interactions

  • Aptamer–drug conjugates (ApDCs)

  • Aptamer-siRNA conjugates

  • Aptamer bi-specifics

Her3 Inhibitor Aptamer’s Intrinsic Anti-tumor Activity Can Be Augmented And Potency Improved By Conjugation to DM1

Aptamer (GRX1461) inhibits BXPC3 tumor growth in a dose dependent manner

  • Highest dose is equivalent to gemcitabine

Aptamer toxin conjugate (GRX1462) has improved potency

  • Highest dose completely inhibits tumor growth

Contact

© 2023 Guardian Therapeutics. All rights reserved.

Welcome to the Guardian Therapeutics and Band Therapeutics website. We do not use any cookies or other technologies on this website, except those that are strictly necessary to enable normal functioning of this web page. View our data protection statement.

Headquarters
Guardian Therapeutics
101 Hartwell Avenue
Suite 2
Lexington, MA 02421
+1 (781) 918-6580

General Inquiries:
info@guardian-rx.com

Business Development Inquiries: businessdevelopment@guardian-rx.com